iPS Cells & Regenerative Medicine– category –
-
Global Leukapheresis Market Growth Accelerates Driven by Cell Therapy, Oncology, and Transplant Demand
GlobeNewswire USA Overview This article summarizes a market research report from The Business Research Company. The report analyzes the global leukapheresis market, noting accelerated growth due to increasing demand in cell therapy, onco... -
Bone Biologics Reports Development Progress in Bone Regeneration, Secures $1.6M from Warrant Exercise
Markets Insider USA Overview Bone Biologics reported significant development progress in its bone regeneration therapeutics in its mid-year shareholder update for 2026. The company, focused on osteoconductive recombinant human proteins f... -
Roche Discontinues Lupus TCE Development, Retains Strong Interest in Autoimmune Cell Therapy
Fierce Biotech Switzerland Overview Roche has halted the development of its T-cell engager (TCE) for systemic lupus erythematosus (lupus) but affirmed its strategic commitment to cell therapy for autoimmune diseases. This decision signal... -
Instinct Bio Debuts on Nasdaq Following SPAC Merger, Infusing New Capital into Cell and Gene Therapy Sector
GlobeNewswire USA Overview Instinct Bio has completed its business combination with Relativity Acquisition Corp., a Special Purpose Acquisition Company (SPAC), and will commence trading on Nasdaq under the ticker "BIOT" on July 24, 2026.... -
First-in-Human Diabetes Cell Therapy Shows Promising Initial Clinical Data
The Medicine Maker UK Overview The world's first human diabetes cell therapy has reportedly shown promising initial data in clinical trials. This therapy holds the potential to reduce insulin dependency in Type 1 diabetes patients by rep... -
Long-Term Safety of iPS Cell Therapy for Spinal Cord Injury Confirmed in Japan
Nippon.com Japan Overview Long-term safety has been confirmed in Japan for a spinal cord injury treatment involving the transplantation of neural progenitor cells derived from induced pluripotent stem cells (iPS cells). A clinical trial ... -
Qatar Issues Stark Warning Against Unapproved Injectable Exosomes, Citing Lack of Scientific Basis and Safety Data
ILoveQatar.net Qatar Overview The Qatar Ministry of Public Health has issued a strong public warning against the use of unapproved injectable exosome products for both medical and cosmetic applications. The Ministry explicitly stated tha... -
Crystalys Therapeutics Secures $35M Series A Funding to Advance Gene Therapy Development
BioBucks USA Overview Crystalys Therapeutics, a gene therapy developer, has raised $35 million in a Series A funding round. This capital will accelerate the research and development of its innovative gene therapy pipeline, targeting unme... -
BioLife Solutions Completes $1 Billion Acquisition to Bolster Cell Therapy Services
RegMedNet USA Overview BioLife Solutions has reportedly completed a $1 billion acquisition, aimed at significantly strengthening its cell therapy service offerings. As a key player in the cell therapy supply chain and manufacturing proce... -
UC Berkeley’s Doudna Lab Redesigns Minimal CRISPR Nucleases with AI, Revolutionizing In Vivo Delivery
CRISPR Medicine News USA Overview Researchers at UC Berkeley's Innovative Genomics Institute (IGI), including Jennifer Doudna, have published a Science paper detailing an AI-powered technique to minimize and redesign CRISPR nucleases. Th...
